Compensatory Immune Suppression Following PD-1/PD-l1 Checkpoint Blockade in Ovarian Cancer

Medicine & Life Sciences

1. Antigens 14%
2. Cell Body 7%
3. Clinical Trials 9%
4. Cytokines 9%
5. Epithelial Cells 5%
6. Immune System 12%
7. Immunity 18%
8. Immunization 12%
9. Immunotherapy 13%
10. Industry 6%
11. Interleukin-10 40%
12. Leg 6%
13. Marketing 8%
14. Melanoma 12%
15. Military Facilities 11%
16. Military Family 12%
17. Neoplasms 31%
18. Neoplastic Stem Cells 8%
19. Non-Small Cell Lung Carcinoma 6%
20. Organized Financing 8%
21. Ovarian Neoplasms 100%
22. Peritoneal Cavity 8%
23. Poisons 5%
24. Preliminary Data 8%
25. Progression-Free Survival 6%
26. Proteins 5%
27. Psychology Rejection 8%
28. T-Lymphocytes 28%
29. Therapeutics 11%
30. Treatment Failure 7%
31. Tumor Microenvironment 15%
32. United States Food and Drug Administration 7%
33. Up-Regulation 10%
34. Vaccines 11%